English
The death of ASICs is greatly exaggerated
By Kenton Williston, dspdesignline.com
March 26, 2007
This week market research firm iSuppli reported that ASIC/ASSP design starts are continuing to plummet. According to the firm, there will be only 5,000 design starts this year, a 50% decrease from the levels seen in the mid-90's. Rival research firm Gartner has even grimmer number, projecting that there will be only 3,200 design starts this year.
March 26, 2007
This week market research firm iSuppli reported that ASIC/ASSP design starts are continuing to plummet. According to the firm, there will be only 5,000 design starts this year, a 50% decrease from the levels seen in the mid-90's. Rival research firm Gartner has even grimmer number, projecting that there will be only 3,200 design starts this year.
|
E-mail This Article | 
|
|
Printer-Friendly Page |
Related News
- Movellus and RTX's SEAKR Engineering Collaborate on Advancing Mission-Critical ASICs
- SEALSQ and IC'ALPS Join Forces to Advance Post-Quantum Secure ASICs for Automotive Functional Safety
- SIAE Microelettronica Selects Ensilica as Key Partner to Design ASICs for Next-Generation Telecom Equipment
- Faraday Partners with Arm to Innovate AI-driven Vehicle ASICs
- Faraday's Launched SerDes Advanced Service to Accelerate ASICs into Production
Breaking News
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- Keysom Unveils Keysom Core Explorer V1.0
Most Popular
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- Ceva, Inc. Announces First Quarter 2025 Financial Results
- Cadence Unveils Millennium M2000 Supercomputer with NVIDIA Blackwell Systems to Transform AI-Driven Silicon, Systems and Drug Design